Overview

Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis
Phase:
Phase 2
Details
Lead Sponsor:
Zymenex A/S
Collaborator:
European Commission